By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Takeda Pharmaceutical and Kyoto University today announced a five-year deal focused on the development of new central nervous system-acting drugs for obesity and schizophrenia.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.
It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.
A proposed bill would require NSF to only fund research that's in "the national interest."
Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.